Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels in type 2 diabetes. Furthermore, it slows intestinal sugar absorption and boosts peripheral glucose usage, potentially leading to weight loss through appetite suppression.
Metformin is the recommended initial treatment for type 2 diabetes by the American Diabetes Association (ADA), either as a standalone medication or combined with other agents or insulin. However, combining it with insulin may lead to hypoglycemia, requiring dose adjustments. Metformin's adverse effects, predominantly gastrointestinal, like nausea, vomiting, and diarrhea, can be mitigated by gradual dosage increase and mealtime administration. It's contraindicated in cases of renal dysfunction, acute myocardial infarction, sepsis, and situations potentially leading to acute renal failure. Vitamin B12 deficiency is a potential long-term side effect.
Another class of insulin sensitizers, Thiazolidinediones (TZDs), including pioglitazone (Actos) and rosiglitazone (Avandia), don't stimulate insulin release from pancreatic β cells, averting hyperinsulinemia risk. TZDs function as peroxisome proliferator-activated receptor-γ (PPARγ) agonists, enhancing insulin sensitivity in various tissues. They can be used alone or combined with other glucose-lowering agents or insulin. The ADA recommends pioglitazone as a secondary or tertiary agent for type 2 diabetes treatment, while rosiglitazone usage is limited due to potential cardiovascular risks. Both drugs are well absorbed orally, bind to serum albumin, and undergo extensive metabolism. TZDs can cause weight gain and osteopenia and increase bladder cancer risk, particularly with pioglitazone. They should be avoided in patients with severe heart failure.
From Chapter 25:
Now Playing
Insulin and Hypoglycemic Drugs
105 Views
Insulin and Hypoglycemic Drugs
1.0K Views
Insulin and Hypoglycemic Drugs
796 Views
Insulin and Hypoglycemic Drugs
855 Views
Insulin and Hypoglycemic Drugs
653 Views
Insulin and Hypoglycemic Drugs
422 Views
Insulin and Hypoglycemic Drugs
173 Views
Insulin and Hypoglycemic Drugs
214 Views
Insulin and Hypoglycemic Drugs
104 Views
Insulin and Hypoglycemic Drugs
93 Views
Insulin and Hypoglycemic Drugs
96 Views
Insulin and Hypoglycemic Drugs
86 Views
Insulin and Hypoglycemic Drugs
85 Views
Insulin and Hypoglycemic Drugs
145 Views
Insulin and Hypoglycemic Drugs
87 Views
See More
Copyright © 2025 MyJoVE Corporation. All rights reserved